Howard Berman

Dr. Matthew N. Brams is a board-certified psychiatrist and one of the nation’s leading clinical trialists in the field of central nervous system (CNS) and psychiatric disorders. With over three decades of experience in clinical practice, academic medicine, and pharmaceutical research, Dr. Brams has served as Principal Investigator on more than 300 clinical trials, ranging from Phase I to Phase IV. His research has directly contributed to multiple FDA approvals of blockbuster medications for conditions such as ADHD, schizophrenia, bipolar disorder, depression, and autism.

Dr. Brams is recognized for his expertise in both pediatric and adult psychiatric populations and is highly sought after for his ability to execute rigorous, high-quality studies across complex neuropsychiatric indications. He currently serves as the Director of Research at Synapsis Bio, where he leads a multidisciplinary team conducting innovative CNS clinical trials. His work has positioned him at the forefront of translational research and drug development in psychiatry.

• American Academy of Child and Adolescent Psychiatry 1996 - present
• Examiner, American Board of Psychiatry and Neurology for Adult and Child Psychiatry Boards 1994- present
• Houston Psychiatric Society 1989-present
• American Medical Association 1983-present
• Texas Medical Association 1983-present
• Member, Harris County Medical Society Fee Complaint Committee 1995 - present

• 1988 Texas License, Registration No. H4183
• 1989 DEA # BB1943871
• 1989 DPS # L0072417
• 1994 American Board of Psychiatry and Neurology Certification in Psychiatry, Certificate #38745
• 1994 American Board of Psychiatry and Neurology Certification in Child and Adolescent Psychiatry, Certificate #3639

Didactic Coursework

• “Neurobiology of ADHD” to PGY-3 psychiatry residents– prep time: 30hrs; 2hr lecture time/yr
• 2 courses of National Board Preparation to PGY-5 and 6 psychiatry fellows – prep time: 5 hrs, lecture time 2hrs/course
• Participation in mock national board exams yearly for 4 fellows, prep time: 2hrs, exam time – 4hrs/exam
• “Transition to Practice” to PGY-4 psychiatry residents; prep time: 10 hrs, lecture time: 2hrs/yr

Non Didactic Coursework

Mentored:

• Aaron Peterson – 2009 – currently in private practice
• Zyed Malik – 2007 – currently Training Director of Child Psychiatry at the University of Arkansas
• Nilesh Patel – 1995 – currently in private practice

Lectures:

• Mao A, Narasimhan M, Wigal S, Wigal T, Ogebe O, Brams M. Attention Deficit Hyperactivity Disorder in Girls – a Clinical Review Symposium Presentation”. International Women’s Mental Health Conference, Melbourne Australia , March 2008.
• Muniz, R, Pestreich, L, McCague, K, Padilla, A, Brams, M, Childress, A. Extended-Release Dexmethylphenidate 30 mg Improves Late-Day Attention Deficit Hyperactivity Disorder (ADHD) Symptom Control in Children with ADHD: A Randomized, Double-Blind Crossover Study. New Clinical Drug Evaluation Unit (National Institute of Mental Health National meeting, June 2010.
• Brams, M. Autism Spectrum Disorders: A Research and Treatment Review for Practitioners. American Academy of Child and Adolescent Psychiatry Annual Meeting, October 2010.
• Brams, M., A Critical Review of Complementary and Alternative Treatments for Autism Spectrum Disorders, American Academy of Child and Adolescent Psychiatry Annual Meeting, October 2009.
• Brams, M, Mao, A, Allen, G, Brams, J, Courchesne, E, Doyle, R, Treadwell-Deering, D, O’Brien, J. Autism Spectrum Disorders: From Basic Science to Clinical Intervention: Specific Interventions for Working with Families of Children with Autism., American Academy of Child and Adolescent Psychiatry Annual Meeting, October 2007.
• Bang, L, Suppatkul, M., Mao, A, Brams, M Clinical Perspective Presentation: “Do Video Games Cause Violent Children: A Multimedia Review” – American Academy of Child and Adolescent Psychiatry Annual Meeting, October 2006
• Mao A, Brams M. Current Concepts in Diagnosis and Treatment of ADHD through the Lifespan. Grand Rounds Presentation at Baylor College of Medicine for Psychiatry Department., September 2009.
• Mao, A; Brams, M Transition to Practice. Location: University of Texas Mental Sciences Institute, Houston, Texas Audience: Child and Adolescent Psychiatry Residents from the University of Texas, Houston Program, July 10, 2003.

Collaborations with: Novartis Pharmaceuticals, Shire Pharmaceuticals, Pfizer Pharmaceuticals, Eli Lily Pharmaceuticals, Johnson & Johnson, GlaxoSmithKline, Noven Pharmaceuticals, Wyeth Pharmaceuticals, Merck Pharmaceuticals, Bristol Meyer Squibb Pharmaceuticals

Representative Research Studies in which was Principal Investigator:

• The combination of XYZ and XYZ in Treatment Resistant Depression without psychotic features. – Eli Lilly
• The study of an XYZ plus a XYZ in combination for treatment resistant depression without psychotic feature in adults. – Eli Lilly
• A phase 2, randomized, double-blind , multi-center, placebo and active controlled, crossover study of XYZ in adults with Attention Deficit Hyperactivity Disorder – Shire
• XYZ versus XYZ in the treatment of Bipolar I Disorder, Manic or Mixed – Eli Lilly
• A randomized, multi center, 8-week, double, placebo-controlled flexible dose study to evaluate the efficacy and safety of XYZ in children and Adolescents with Major Depression – SmithKline Beecham
• Placebo-Controlled XYZ Monotherapy in the Treatment of Bipolar I Depression – Eli Lilly
• XYZ Plus XYZ Combination Therapy in Treatment –Resistant Depression: A Dose Ranging Study – Eli Lilly
• A Randomized, multi-center, 10-Week, double-blind, placebo controlled, flexible-dose study to evaluate the efficacy and safety of XYZ in children and adolescents with Obsessive-Compulsive Disorder – SmithKline Beecham
• A randomized, double-blind comparison of the time course of response to two extended-release oral delivery systems for XYZ in pediatric patients with attention deficit hyperactivity disorder in an analog classroom setting. - Celltech
• The effect of XYZ on bone mineral density in pediatric subjects with anorexia nervosa: A double-blind, placebo controlled study – Ortho-McNeil
• A prospective, Multicenter, open label study of XYZ in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practices – Bristol-Meyers Squibb
• An 8-week, randomized, double-blind, parallel group, placebo controlled, Multicenter, fixed dose study comparing the efficacy and safety of XYZ or XYZ to placebo in moderately to severely depressed patients with major depressive disorder – GlaxoSmithKline
• A Multicenter, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of 8 weeks of XYZ tablets as adjunctive treatment for excessive sleepiness in adults with major depressive disorder, sleepiness and fatigue followed by a 12 week open label period – Cephalon
• An open label, multi center study to assess tolerability, effectiveness and quality of life associated with attention deficit hyperactivity disorder in a community practice setting – Shire
• An 8-week, Multicenter, randomized, double-blind, placebo-controlled, flexible dose comparison of extended release XYZ to assess the efficacy, safety, and effects on health outcomes in the treatment of adults with attention-deficit hyperactivity disorder. – Bristol Meyers Squibb
• A comparison of fasting triglyceride levels in cohorts with schizophrenia and related disorders treated chronically with XYZ and XYZ and typical antipsychotics. – Eli Lilly
• An international, Multicenter, large simple trial to compare the cardiovascular safety of XYZ and XYZ. – Pfizer
• A Multicenter, double-blind, randomized, placebo-controlled, cross-over study evaluating the efficacy and safety of XYZ in female adolescents diagnosed with attention deficit hyperactivity disorder – Novartis
• XYZ Versus Placebo in the treatment of mania in adolescents with bipolar I disorder – Eli Lilly
• A Multicenter, double-blind, double-dummy, placebo controlled, randomized, parallel group study of the efficacy and safety of XYZ versus placebo and XYZ in subjects with schizophrenia – GlaxoSmithKline
• A double-blind, placebo-controlled evaluation of the safety and efficacy of XYZ in pediatric depression – Forest Research
• A 12-Week, Multicenter, randomized, double-blind, double-dummy, parallel group, active controlled, escalating dose study to compare the effects of sexual functioning of XYZ and XYZ in subjects with major depressive disorder – GlaxoSmithKline
• XYZ versus Placebo in the Treatment of elderly patients with major depressive disorder – Eli Lilly
• A randomized, double-blind, parallel-group, placebo-controlled fixed dose study evaluating the efficacy and safety of XYZ in elderly outpatients diagnosed with major depressive disorder. – GlaxoSmithKline
• Efficacy of high dose XYZ in a controlled fixed dose response trial for the treatment of schizophrenia and schizoaffective disorder – Eli Lilly
• Guiding dose increases in patients incompletely responsive to usual doses of XYZ by determining plasma XYZ Concentrations: A randomized, double-blind study – Eli Lilly
• A double-blind flexible dose comparison of XYZ and Placebo in the treatment of major depressive disorder – Forest Research
• A double-blind flexible dose comparison of XYZ, XYZ and placebo in the Treatment of generalized anxiety disorder – Forest Research
• A phase IIIB, open label, multi center study to assess safety tolerability and effectiveness associated with the use of XYZ in adults with attention deficit hyperactivity disorder and evaluate an ADHD-specific novel quality of life measure – Shire
• XYZ versus XYZ and placebo in the Treatment of patients with major depression – Eli Lilly
• A randomized, multi center, single-blind, placebo-controlled cross-over study comparing the efficacy of XYZ versus XYZ in children with attention deficit hyperactivity disorder in an analog classroom setting – Novartis
• XYZ Combination versus XYZ in the treatment if bipolar I depression – Eli Lilly
• A Phase 2, randomized, double-blind, multi-center, placebo and active controlled, crossover study of XYZ in adults with attention deficit hyperactivity disorder – Shire
• A double-blind randomized study comparing intramuscular XYZ with placebo in the treatment of patients with schizophrenia – Eli Lilly
• A comparison of XYZ dosing strategies in treatment of patients with major depression – Eli Lilly
• A Phase II, randomized, double-blind, Multicenter, placebo and active controlled crossover study of XYZ in adolescents with attention deficit hyperactivity disorder. – Shire
• A randomized, multi center, double-blind, cross-over study comparing the efficacy and safety of XYZ versus placebo in children (6-12 years) with attention deficit hyperactivity disorder in a laboratory classroom setting – Novartis
• A randomized, double-blind, placebo-controlled, multi center study to evaluate the efficacy and tolerability of XYZ 1000 -2000 mg/d in the treatment of manic episodes of bipolar disorder over 3 weeks – Novartis
• Population Pharmacokinetic study in adolescent patients with schizophrenia or bipolar I disorder treated with XYZ – Eli Lilly
• A randomized, multi-center, double-blind, cross over study comparing the efficacy and safety of XYZ versus XYZ and placebo in children with attention deficit hyperactivity disorder in a laboratory classroom setting. - Novartis
• A phase III, randomized, double-blind, multi center, placebo controlled parallel group, forced dose titration, safety and efficacy study of XYZ in adults with attention deficit hyperactivity disorder – Shire
• A Phase III, multi-center, 12 month, open label safety study of XYZ in Adults with attention deficit hyperactivity disorder – Shire
• A phase II, randomized, double-blind, multi-center, placebo controlled, crossover study of XYZ in Adults with attention deficit hyperactivity disorder – Shire
• A Phase II study to assess to assess the safety, tolerability and efficacy of XYZ administered to children and adolescents aged 6-17 with attention deficit hyperactivity disorder – Shire
• A double-blind randomized study comparing intramuscular XYZ to oral XYZ and placebo in the maintenance of patients with schizophrenia – Eli Lilly
• Efficacy, safety and tolerability of XYZ in the treatment of children aged 6 – 17 years with ADHD-associate insomnia. A multi-center, randomized, double-blind placebo-controlled study. – Sanofi Aventis
• A multi, double blind, randomized, placebo controlled, parallel group study with three fixed doses of XYZ in the treatment of children and adolescents with Autistic disorder – Bristol Meyers Squibb
• A 52-week, open label, multi center study of the safety and tolerability of XYZ flexibly dosed in the treatment of children and adolescents with autistic disorder – Bristol Meyers Squibb
• An 8-week, randomized, double-blind, fixed dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of XYZ in the treatment of major depressive disorder followed by a 52-week open label extension – Novartis
• Predicting response to XYZ treatment through identification of early-onset of antipsychotic drug action in schizophrenia- Eli Lilly
• A multi-center, randomized, 1-week, double-blind, placebo controlled study to evaluate the safety and tolerability of abrupt discontinuation of XYZ in outpatients with major depressive disorder who completed 8 weeks of open-label treatment with XYZ once daily – Sanofi Aventis
• A multi-center, randomized, double-blind, placebo controlled study of two fixed oral doses of XYZ in the treatment of child and adolescent patients, ages 10-17 years with bipolar I disorder, manic or mixed episodes with or without psychotic features – Otsuka
• A multi-center, randomized, 8 week, double-blind, placebo-controlled study followed by a 6-month open-label extension to evaluate the efficacy and safety of XYZ in Peri and postmenopausal women with major depressive disorder – Wyeth

• Brams, M, Weisler, R, Findling RL, Gasior M, Et al Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clinical 2012. July: 73 (7):977-83
• Brown TE. Brams M. Gao J. Gasior M. Childress A. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. Postgraduate Medicine. 122(5):7-17, 2010 Sep.
• Wigal T. Brams M. Gasior M. Gao J. Squires L. Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behavioral & Brain Functions [Electronic Resource]: BBF. 6:34, 2010.
• Brams M. Moon E. Pucci M. Lopez FA Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Current Medical Research & Opinion. 26(8):1809-25, 2010 Aug.
• Brams M. Mao AR. Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgraduate Medicine. 120(3):69-88, 2008 Sep.
• Brams M. Muniz R. Childress A. Giblin J. Mao A. Turnbow J. Borrello M. McCague K. Lopez FA. Silva R. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs. 22(8):693-704, 2008.
• Muniz R. Brams M. Mao A. McCague K. Pestreich L. Silva R. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. Journal of Child & Adolescent Psychopharmacology. 18(3):248-56, 2008 Jun.
• Silva RR. Muniz R. Pestreich L. Brams M. Mao AR. Childress A. Wang . Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 47(2):199-208, 2008 Feb.
• Silva RR. Muniz R. Pestreich L. Childress A. Brams M. Lopez FA. Wang J. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder. Journal of Child & Adolescent Psychopharmacology. 16(3):239-51, 2006 Jun.
• Brams, MN: Review of Taking Charge of ADHD, Journal of the American Academy of Child and Adolescent Psychiatry, Volume 41, number 1, January 2002, pages 101-102.
• Mao, A , Treadwell-Deering D, Brams M, Van Wattum P. Impact on Parents of Raising a Child with Psychiatric Illness and/or Developmental Disability. Kaplan and Sadock, Comprehensive Textbook of Psychiatry. Ninth Edition Volume II. pp. 3895-3903